Femasys
FEMY
Market cap $28.7M

0.8839 USD

-0.0529

5.65%

At close Jul 18, 4:00 PM EDT

After hours

0.8800

-0.0039

0.44%

1 day

-5.65%

5 days

-4.44%

1 month

0.44%

3 months

-26.34%

6 months

-25.72%

Year to date

-19.65%

1 year

-20.37%

5 years

-92.63%

10 years

-92.63%

About: Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Employees: 71

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,321 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 3

84% more capital invested

Capital invested by funds: $2.62M [Q4 2024] → $4.82M (+$2.2M) [Q1 2025]

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

6.42% more ownership

Funds ownership: 10.42% [Q4 2024] → 16.84% (+6.42%) [Q1 2025]

0% more funds holding

Funds holding: 29 [Q4 2024] → 29 (+0) [Q1 2025]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$6

579%

upside

Avg. target

$9

918%

upside

High target

$12

1,258%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Emily Bodnar	1,258%upside $12	Buy Reiterated	25 Jun 2025
Jones Trading Catherine Novack	579%upside $6	Buy Maintained	13 May 2025

See Analyst Rankings

Financial journalist opinion

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

-- Milestone expands global reach and reinforces commitment to accessible, first-line infertility solutions -- ATLANTA, July 01, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces the achievement of regulatory approvals in Australia and New Zealand for its next-generation infertility solutions: FemaSeed® for first-line intratubal insemination treatment and FemVue® for diagnostic evaluation. “Securing regulatory approvals in Australia and New Zealand mark another important step in expanding global access to our innovative infertility solutions,” said Kathy Lee-Sepsick, CEO and Founder of Femasys.

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces Conformité Européene (CE) mark certification under European Union Medical Device Regulation (EU MDR 2017/745) of the Class III FemBloc blended polymer component, marking the first regulatory approval in the world for the FemBloc® System for non-surgical female permanent birth control. After European Medicines Agency (EMA) review, the Notified Body has granted CE mark certification.

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

--New CCO to Lead U.S. Commercialization of Fertility Products, Including FemaSeed ® , and Expand Strategic Global Partnerships Across Full Portfolio-- ATLANTA, June 17, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc. (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the appointment of Kelley Nicholas as Chief Commercial Officer (CCO). Ms. Nicholas will be responsible for leading the execution and optimization of Femasys' commercial strategy to drive revenue growth across its entire portfolio, with a particular focus on expanding the U.S. infertility market and building key international partners.

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products announces a partnership with Carolinas Fertility Institute (CFI), one of America's best fertility clinics. Carolinas Fertility Institute will provide the Company's FemaSeed® intratubal insemination product as an infertility treatment option to patients throughout its network in North Carolina.

Femasys Announces Partnership with Carolinas Fertility Institute, One of America's Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement.

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

Zacks Investment Research

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

-- Company delivers on mission to transform women's health with innovative solutions, including FemaSeed ® for first-line infertility treatment and FemBloc ® non-surgical permanent birth control (full system approval pending in Europe) -- ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update.

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

Zacks Investment Research

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Femasys Inc. (FEMY) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.19 per share a year ago.

Femasys Inc. (FEMY) Reports Q4 Loss, Lags Revenue Estimates

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

-- Company expands commercial product offering with FemBloc ® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain -- ATLANTA, March 27, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the year ended December 31, 2024 and provides a corporate update.

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

Femasys continues to expand access and market share for its first-line infertility treatment option Femasys continues to expand access and market share for its first-line infertility treatment option

Femasys Announces Partnership with CNY Fertility, National Conglomerate Network of Fertility Centers, to Offer FemaSeed in its 11 Locations

See News Rankings

Charts implemented using Lightweight Charts™